Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication

Journal of Gastroenterology and HepatologyHorii T, Suzuki S, Takano C, et al. | June 22, 2021

Advertisement

As disruption in the gut microbiome may occur because of Helicobacter pylori eradication, researchers herein examined the short-term impact of minimum antibiotic treatment—a 7-day vonoprazan and low-dose amoxicillin regimen (VA-dual therapy)—on gut microbiota as well as compared it with that of vonoprazan-based triple therapy (VAC-triple therapy). They recruited and randomized 59 patients with H. pylori infection to the VAC-triple therapy or VA-dual therapy groups, according to the first-line H. pylori treatment received. Before treatment initiation as well as 1 and 8 weeks after eradication therapy completion, the patients provided fecal samples for evaluation. Findings suggest that VA-dual therapy induced minimal changes in the diversity and relative abundance of gut microbiota compared with VAC-triple therapy.

Read the full article on Journal of Gastroenterology and Hepatology

Advertisement